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Summary and Implications 
 Holstein-Friesian heifers (n = 178) from a central Iowa 
dairy farm were enrolled in a study to determine whether 
prepartum intramammary treatment of dairy heifers with 
pirlimycin hydrochloride would reduce the prevalence of 
intramammary infection (IMI) and lower the somatic cell 
count (SCC) during early lactation or improve 305-day 
mature equivalent milk production. Heifers were assigned to 
treatment and control groups, and treated heifers received a 
single 50-mg dose of pirlimycin in each mammary quarter 
approximately 10 days prior to parturition.  
 Treated heifers had a higher overall cure rate and cure 
rate for IMI caused by coagulase negative staphylococci 
(CNS), but postpartum California mastitis test scores and 
prevalence of chronic IMI did not differ between groups. 
Mature equivalent 305-day milk production did not differ 
between treatment groups (trend for higher production when 
treated, p = 0.085). No pirlimycin residues were detected in 
postpartum milk samples. 
 
Introduction 
 Research data accumulated over the past 20 years 
suggests that a high proportion of dairy heifers develop IMI 
prior to calving. Fox et al. reported that the prevalence of 
IMI in heifers was greatest during the last trimester of 
gestation. Heifers infected with staphylococci prior to 
calving tend to have higher numbers of leukocytes in 
mammary secretions and often develop scarring of udder 
tissue, which may have an impact on future milk production. 
Studies published to date agree that coagulase-negative 
staphylococci  (CNS) is the most common cause of 
prepartum IMIs in dairy heifers, with prevalences of other 
pathogens varying from one study to the next. Given the 
high prevalence of mastitis pathogens in the mammary 
glands of prepartum heifers, the potentially detrimental 
effects of IMI on future productivity, and the possibility of 
introducing or perpetuating contagious mastitis pathogens in 
dairy herds, recent research has focused on prepartum 
intramammary antimicrobial treatment of heifers to reduce 
the prevalence of IMI during early lactation. Several studies 
have reported prepartum antimicrobial treatment of dairy 
heifers decreased the prevalence of IMI after calving, and 1 
study reported a significant economic benefit through 
increased milk production. However, only 1 of these studies 
evaluated the effect of prepartum treatment with pirlimycin 
hydrochloride on the prevalence of mastitis pathogens 
during early lactation in dairy heifers, and although a 
significant reduction in the prevalence of postpartum IMI 
was found, the authors did not evaluate the effect of 
treatment on milk somatic cell count (SCC) or milk 
production. In addition, although the study included cattle 
from 2 herds, only 42 heifers treated with pirlimycin were 
included, and no data on pirlimycin residues in milk from 
treated heifers were provided. The potential for 
antimicrobial residues in milk from heifers treated prior to 
parturition has been studied previously, but to our 
knowledge, no study has evaluated residues in heifers 
treated with pirlimycin before parturition. 
 The purpose of this study was to determine whether 
prepartum intramammary treatment of dairy heifers with 
pirlimycin would reduce the prevalence of IMI, lower SCC 
during early lactation, and improve 305-day mature 
equivalent (ME) milk production. In addition, we wanted to 
determine whether prepartum intramammary treatment of 
dairy heifers with pirlimycin would result in detectable 
pirlimycin residues in milk collected after parturition. 
 
Materials and Methods 
 One hundred seventy eight Holstein heifers on a 1200 
cow commercial central Iowa dairy were used in the study. 
Heifers were enrolled longitudinally in the study on the 
basis of expected calving date over an 8 month period. 
Approximately 10 days prior to calving, cattle were 
systematically and equally assigned to 1 of 2 groups 
(treatment and untreated control), with every other heifer 
assigned to the treatment group.  
 
Treatment and Sample Collection 
 Prepartum mammary gland secretions were aseptically 
collected from all functional mammary quarters of all cattle 
at the time of enrollment. Prior to collection of these 
samples, teats were treated with a germicidal dip, dried with 
individual towels, and vigorously scrubbed with cotton pads 
soaked in 70% isopropyl alcohol. Personnel collecting 
samples wore latex gloves. Following sample collection, 
animals in the treatment group received a single 50-mg dose 
of pirlimycin hydrochloride (Pirsue, Pfizer Animal Health) 
by aseptic intramammary infusion into each mammary 
quarter. Control cattle did not receive any intramammary 
injections prior to calving. No systemic antimicrobials were 
administered to cattle in either group prior to calving. After 
sample collection and treatment, teats were dipped in an 
external teat sealant  (Stronghold, West Agro, Inc.). 
 For each heifer, the date when prepartum mammary 
gland secretions were collected and the calving date were 
recorded. Aseptic mammary quarter foremilk samples were 
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collected from all heifers approximately 1 and 4 weeks after 
calving and were submitted for bacterial culture using NMC 
protocols. California mastitis test (CMT) scores were 
obtained at calving. Actual 305-day ME milk production 
were recorded after each animal completed its first lactation. 
 A composite foremilk sample consisting of milk from 
all lactating mammary quarters was collected late on day 
one or day 2 of lactation and tested on farm for pirlimycin 
residues with a commercial test kit (Delvotest-P, DSM Food 
Specialties USA, Inc.)  
 Mammary quarters from which bacteria were isolated 
prior to calving were classified as cured if bacteria were not 
isolated from any milk sample obtained after calving and 
were classified as chronically infected if the same bacteria 
isolated prior to calving were isolated from both milk 
samples obtained after calving. Mammary quarters were 
classified as newly infected if the same new bacteria were 
isolated from at least 2 consecutive milk samples collected 
after calving. 
 
Data Analysis 
 Proportions of mammary quarters infected prior to 
parturition, cured, chronically infected, and newly infected 
were compared between groups by means of the χ2 or Fisher 
exact test.  Mammary quarters were treated as individuals 
because all quarters included in the data analysis had 
subclinical IMIs and communication between quarters was 
considered unlikely.  A previous report on pre-partum 
treatment of heifers used a similar approach to analyze data.  
Milk production data were analyzed by means of two-way 
ANOVA on ranks. Days from treatment to calving and 
CMT data and days from calving to collection of the first 
and second postpartum milk samples were analyzed by 
means of Kruskal-Wallis one-way ANOVA on ranks. The 
Bonferroni multiple comparison test was used for pair-wise 
comparisons. For all analyses, values of P ≤ 0.05 were 
considered significant. 
 
Results 
 A total of 178 heifers were enrolled in the study (120 
with complete data: 66 treated and 54 control). Twenty-
seven quarters were excluded because intramammary 
antimicrobial treatment was given at the time of calving due 
to clinical mastitis (6 of 17 treated quarters and 2 of 10 
control quarters that were excluded had gram-negative 
mastitis), 6 quarters were excluded because of missing data, 
and 4 quarters were excluded because the quarters were 
non-functional after calving. Thus, data were collected for 
443 quarters (242 treated and 201control).  
Median time from collection of prepartum mammary 
gland secretions to calving was 9 days (range, 1 to 20 days) 
with no significant difference between treatment groups (P 
= 0.796). Median times between parturition and collection 
of the first and second postpartum milk samples were 6 days 
(range, 0 to 32 days) and 33 days (range, 15 to 92 days), 
with no significant difference between treatment groups (P 
= 0.428). 82% of heifers (98/120) were found to have 
prepartum IMIs.  
There was no difference in prevalence of prepartum IMI 
between treatment groups (P = 0.470) (Table 1). Proportion 
of mammary quarters classified as cured was significantly 
higher for treated quarters (P = 0.017). CNS was most 
commonly isolated from prepartum mammary gland 
secretions, followed by environmental streptococci (Table 
2). Proportion of mammary quarters with prepartum IMI 
caused by CNS that were classified as cured following 
parturition was significantly higher for the treatment group 
(P = 0.013). Mammary quarter CMT scores obtained at the 
time of calving were not significantly different between 
treatment groups (P = 0.652). For both groups, median 
CMT score was 1 (ranges, 0 to 4 and 1 to 3 for treatment 
and control groups, respectively).  
 Actual 305-day ME milk production data was available 
for 105 (59 treated and 46 control) heifers. Median 305-day 
ME milk production was 11,417 kg (range, 3,012 to 16,914 
kg) for treated heifers and 10,476 kg (range, 3,801 to 16,252 
kg) for control heifers. No significant (P ≥ 0.085) 
differences in actual 305-day ME milk production were 
detected between groups. Also, no significant (P ≥ 0.167) 
difference in actual 305-day ME milk production was 
detected between heifers that had a prepartum IMI and those 
that did not. Results of the commercial test kit for 
pirlimycin residues in all milk samples were negative.  
 Results of the present study suggest that prepartum 
treatment of heifers significantly reduced the prevalence of 
early lactation IMI, particularly IMI caused by CNS. There 
was no significant differences between groups in CMT 
scores at calving or in 305-day ME milk production (trend 
of higher production at p = 0.085, for treated animals). 
There were also no detectable pirlimycin residues 
(Delvotest-P) on day 2 of lactation for all animals. 
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Table 1⎯Outcome of prepartum intramammary treatment with pirlimycin hydrochloride among dairy heifers. 
  
 
Herd 
 
Group 
No. of 
heifers 
No. of 
quarters 
No. (%) of 
quarters with 
prepartum IMI 
No. (%) of 
quarters cured 
No. (%) of 
quarters 
chronically 
infected 
No. (%) of 
quarters newly 
infected 
 Treated 66 242 99 (41) 88 (89)a 2 (1) 3 (1) 
 Control 54 201 90 (45) 67 (74)a 8 (4) 3 (1) 
 
a In each column, values with the same letter superscript were significantly (P < 0.05) different. 
Mammary quarters from which bacteria were isolated prior to calving were classified as cured if bacteria were not isolated 
from any milk sample obtained after calving. Mammary quarters were classified as chronically infected if bacteria were 
isolated prior to calving and the same bacteria were isolated from both milk samples obtained after calving. Mammary 
quarters were classified as newly infected if the same new bacteria were isolated from at least 2 consecutive milk samples 
collected after calving. IMI = Intramammary infection. 
 
 
 
Table 2⎯Pathogens isolated from prepartum mammary gland secretions and postpartum milk samples from heifers that 
underwent prepartum intramammary administration of pirlimycin and from untreated control heifers. 
 
 
Herd 
 
Pathogen 
 
Group 
No. of quarters 
with prepartum 
IMI 
No. (%) of 
quarters cured 
No. of quarters 
chronically 
infected 
No. of quarters 
newly infected 
 CNS      
  Treated 91 80 (88)a 2 0 
  Control 73 52 (71)a 7 3 
 Streptococcus spp      
  Treated 6 6 (100) 0 1 
  Control 11 10 (91) 0 0 
 Staphylococcus aureus      
  Treated 0 NA 0 0 
  Control 4 3 (75) 1 0 
 Gram-negative 
bacteria 
     
  Treated 2 2 (100) 0 2 
  Control 1 1 (100) 0 0 
 Mixed bacteria      
  Treated 0 NA 0 0 
  Control 1 1 (100) 0 0 
 
a In each column, values with the same letter superscript were significantly (P < 0.05) different. 
CNS = Coagulase-negative staphylococci. Streptococcus spp includes streptococci other than Streptococcus agalactiae. 
Mixed bacteria typically consisted of staphylococci and streptococci other than S agalactiae. See Table 1 for remainder of 
key. 
 
 
